The province of Quebec has announced that it will include sitagliptin [Januvia], under some reimbursement criteria

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.564, 2008-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The US HHS has announced that the government will no longer pay for US immigrants' chemotherapy under Medicaid

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 543, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Discovery of JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes.

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 557-568

Bentham Science Publishers

Access to resources Recommend Favorite

The UK government has announced a genetics white paper

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 419, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Sitagliptin

By Lyseng-Williamson Katherine A.

Drugs, Vol. 67, Iss. 4, 2007-01 ,pp. : 587-597

Adis International

Access to resources Recommend Favorite

Health Canada has announced the withdrawal of marketing authorisation for Prexige [lumiracoxib]

Reactions Weekly, Vol. 1, Iss. 1173, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite